CVRx, Inc. CVRX
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-15.5
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $56.7M | -$53.3M | $48.3M | -$40.8M | $39.3M |
| 2024 | $51.3M | -$60.0M | $43.0M | -$40.5M | $71.1M |
| 2023 | $39.3M | -$41.2M | $33.0M | -$39.6M | $75.9M |
| 2022 | $22.5M | -$41.4M | $17.5M | -$43.4M | $109.2M |
| 2021 | $13.0M | -$43.1M | $9.4M | -$28.9M | $146.0M |
| 2020 | $6.1M | -$14.1M | $4.6M | -$16.4M | -$293.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -15.5 (distress)
- Working capital / assets 0.843
- Retained earnings / assets -5.636
- EBIT / assets -0.489
- Equity / liabilities 0.601
Source: SEC EDGAR filings · CIK 0001235912 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.